Basal Cell Carcinoma Market
Key Highlights
- According to the Skin Cancer Foundation, Basal cell carcinoma (BCC) is the most common form of skin cancer. An estimated 3.6 million cases of Basal cell carcinoma are diagnosed in the US annually. More than 419,000 cases of skin cancer in the US each year are linked to indoor tanning, including about 245,000 basal cell carcinomas, 168,000 squamous cell carcinomas and 6,200 melanomas, Those who have ever tanned indoors have a 83% increased risk of developing squamous cell carcinoma and a 29% increased risk of developing basal cell carcinoma, Any history of indoor tanning increases the risk of developing basal cell carcinoma before age 40 by 69%.
- Basal Cell Carcinoma Market Companies are working in the market like MedC Biopharma Corporation, AiViva BioPharma, MediWound, Kintara Therapeutics, IO Biotech, Sirnaomics, Aresus Pharma, Epitome Pharmaceuticals, Transgene, Senhwa Biosciences, Palvella Therapeutics, Suzhou Kintor Pharmaceuticals, Leaf Vertical, and others.
- Basal Cell Carcinoma epidemiology is segmented as Total Basal Cell Carcinoma Prevalent Cases, Total Basal Cell Carcinoma Nonmelanoma Prevalent cases, Basal Cell Carcinoma Subtype-specific Cases, Basal Cell Carcinoma Prevalent cases, and Basal Cell Carcinoma Stage-Specific Prevalent cases in the Basal Cell Carcinoma market report.
Request a sample to unlock the CAGR for Basal Cell Carcinoma Market
DelveInsight's "Basal Cell Carcinoma Market Insights, Epidemiology, and Market Forecast — 2032" report delivers an in-depth understanding of the Basal Cell Carcinoma, historical and forecasted epidemiology as well as the Basal Cell Carcinoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Basal Cell Carcinoma market report provides current treatment practices, emerging drugs, Basal Cell Carcinoma market share of the individual therapies, current and forecasted Basal Cell Carcinoma market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Basal Cell Carcinoma treatment practice/algorithm, and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Geography Covered
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
Study Period: 2019–2032
Basal Cell Carcinoma Treatment Algorithm and Disease Understanding
The DelveInsight’s Basal Cell Carcinoma market report gives a thorough understanding of Basal Cell Carcinoma by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis, and treatment. Basal cell carcinoma (BCC) is the most common form of skin cancer and the most frequently occurring form of all cancers. Basal cell carcinoma mostly arises on sun-damaged skin and rarely develops on the mucous membranes or palms and soles. Basal cell carcinoma is usually a slow-growing tumor for which metastases are rare. Although rarely fatal, Basal cell carcinoma can be highly destructive and disfigure local tissues when treatment is inadequate or delayed. On clinical examination, Basal cell carcinoma usually appears as flesh- or pink-colored, pearly papules with overlying ulceration or telangiectatic vessels. Basal cell carcinoma occurs on the head or neck in the majority of cases, but can involve the trunk and extremities.
More than 26 different subtypes of Basal cell carcinoma, but the more common, distinctive, clinicopathologic types include: nodular, micronodular, superficial, morpheaform, infiltrative and fibroepithelial (also known as fibroepithelioma of Pinkus). Combinations of these types can occur as well. The majority of Basal cell carcinomas are amelanotic, but variable amounts of melanin may be present within these tumors.
Basal Cell Carcinoma Diagnosis
A skin biopsy is necessary for clinical confirmation of Basal cell carcinoma. A shave, punch, or excisional biopsy are all options, taking care to include some portion of the dermis in the specimen to differentiate between superficial and other invasive histologic subtypes of Basal cell carcinoma. Dermoscopy can be beneficial to the experienced clinician, aiding in the diagnosis of non-pigmented and pigmented Basal cell carcinomas.
The differential diagnosis of Basal cell carcinoma includes adnexal tumors with follicular, sweat gland, or sebaceous differentiation and certain types of Squamous cell carcinomas. Nodular Basal cell carcinoma may be confused with trichoblastoma or trichoepithelioma. Superficial Basal cell carcinoma may mimic some inflammatory dermatoses such as psoriasis and eczema. Morphea-like Basal cell carcinoma may be confused with a plaque of morphea or a scar. In these cases, histopathological helps to establish the diagnosis of Basal cell carcinoma.
Basal Cell Carcinoma Treatment
Therapy selection depends on the patient's age and gender as well as the site, size, and type of lesion. No single treatment method is ideal for all lesions or all patients. A biopsy should be performed in all patients with suspected Basal cell carcinoma to confirm the diagnosis and determine the histologic subtype.
Treatment of Basal cell carcinoma is usually surgical, but some forms of Basal cell carcinoma are amenable to medical treatment or radiation therapy. The various types of therapy include Mohs micrographic surgery (MMS), standard surgical excision, EDC, radiation, photodynamic therapy, cryosurgery, topical therapies, and systemic medications such as Vismodegib.
Mohs micrographic surgery (MMS) provides the best long-term cure rate of any treatment modality for Basal cell carcinoma. It is the gold standard for treating high-risk BCCs and recurrent BCCs because of its high cure rate and tissue-sparing benefit. The high cure rate is attributed to an examination of 100% of all the tissue margins when compared with standard vertical sectioning, that only examines less than 1% of the outer peripheral and deep margins.
Basal Cell Carcinoma Epidemiology
The Basal Cell Carcinoma epidemiology section provides insights about historical and current Basal Cell Carcinoma patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Key Findings
- According to the Skin Cancer Foundation, Basal cell carcinoma (BCC) is the most common form of skin cancer. An estimated 3.6 million cases of Basal cell carcinoma are diagnosed in the US annually. More than 419,000 cases of skin cancer in the US each year are linked to indoor tanning, including about 245,000 basal cell carcinomas, 168,000 squamous cell carcinomas and 6,200 melanomas, Those who have ever tanned indoors have a 83% increased risk of developing squamous cell carcinoma and a 29% increased risk of developing basal cell carcinoma, Any history of indoor tanning increases the risk of developing basal cell carcinoma before age 40 by 69%.
- The disease epidemiology covered in the report provides historical as well as forecasted Basal Cell Carcinoma epidemiology [segmented as Total Prevalent Cases of Basal Cell Carcinoma, Total Nonmelanoma Prevalent cases, Subtype-specific Cases of Basal Cell Carcinoma, Basal Cell Carcinoma Prevalent cases, and Stage-Specific Prevalent cases of Basal Cell Carcinoma] in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.
Country Wise- Basal Cell Carcinoma Epidemiology
This section provides glimpse of the Basal Cell Carcinoma epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
Learn more about the evolving epidemiology trends and key developments: Basal Cell Carcinoma Epidemiology Forecast
Basal Cell Carcinoma Drug Chapters
The drug chapter segment of the Basal Cell Carcinoma report encloses the detailed analysis of Basal Cell Carcinoma marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Basal Cell Carcinoma clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.
Basal Cell Carcinoma Marketed Drugs
ERIVEDGE (vismodegib): Roche
It is a hedgehog pathway inhibitor indicated for the treatment of adults with metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery, and who are not candidates for radiation. ERIVEDGE is a capsule taken once-daily to treat adults with a type of skin cancer, called basal cell carcinoma; works by blocking abnormal functioning of the Hedgehog cell signaling pathway. Abnormal activation of this pathway is responsible for tumor development in most basal cell carcinomas.
ODOMZO (sonidegib): Novartis
It is an oral, selective smoothened (SMO) inhibitor that regulates the hedgehog (Hh) signaling pathway, which plays a critical role in stem cell maintenance and tissue repair, as well as in advanced basal cell carcinoma. It is approved by the FDA for the treatment of adult patients with locally advanced basal cell carcinoma (laBCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy.
LIBTAYO (cemiplimab-rwlc): Regeneron and Sanofi
It is a fully-human monoclonal antibody targeting the immune checkpoint receptor PD-1 on T-cells. By binding to PD-1, Libtayo has been shown to block cancer cells from using the PD-1 pathway to suppress T-cell activation. On February 2021, the FDA approved it as the first immunotherapy indicated for patients with advanced basal cell carcinoma (BCC) previously treated with a hedgehog pathway inhibitor (HHI) or for whom an HHI is not appropriate. Full approval was granted for patients with locally advanced BCC and accelerated approval was granted for patients with metastatic BCC.
ALDARA (Imiquimod): 3M Pharmaceuticals
It is an immunomodulatory drug that stimulates both the innate and cell-mediated arms of the immune system while simultaneously exhibiting direct pro-apoptotic effects on tumor cells. It approved by the FDA in immunocompetent adults with biopsy-confirmed, primary superficial basal cell carcinoma (sBCC) that is less than 2cm in diameter and located on the trunk, neck, or extremities (excluding hands and feet).
Note: Detailed Current therapies assessment will be provided in the full report of Basal Cell Carcinoma
Basal Cell Carcinoma Emerging Drugs
AIV001 is a novel formulation of a multi-kinase inhibitor combined with AiViva's proprietary delivery technology, designed for prolonged drug release via intradermal treatment. AIV001 targets multiple pathways to reduce fibroplasia in overlapping phases of wound healing and scarring; targets VEGFR to limit the inflammation and fibrosis associated with rosacea; and inhibits or reduces neovascularization and cell proliferation associated with certain cancers.
STP705, is a dual TGF-β1/COX-2 inhibitor, being developed by Sirnaomics. TGF-β1 and COX-2 are known as gatekeeper targets for oncology and fibrosis disease drug development. TGF-β1 regulates a broad range of cellular processes, including cell proliferation, differentiation, apoptosis, extracellular matrix production, angiogenesis, inflammation and immune response, while COX-2 is a proinflammatory and proliferative mediator. STP705 leverages a PNP delivery platform in a locally administered formulation for direct administration to diseased tissue.
Patidegib is Topical Gel, developed by Pellepharm, is an investigational treatment, and is designed to reduce the BCC tumor burden in patients with Gorlin Syndrome and High Frequency BCC (HF-BCC) by blocking the disease at its source within the hedgehog signaling pathway.
Note: Detailed emerging therapies assessment will be provided in the full report of Basal Cell Carcinoma.
Basal Cell Carcinoma Market Outlook
Basal cell carcinoma (BCC) is the most common form of skin cancer and the most frequently occurring form of all cancers. Therapy selection depends on the patient's age and gender as well as the site, size, and type of lesion. No single treatment method is ideal for all lesions or all patients. Treatment of Basal cell carcinoma is usually surgical, but some forms of BCC are amenable to medical treatment or radiation therapy. The various types of therapy include Mohs micrographic surgery (MMS), standard surgical excision, radiation, photodynamic therapy, cryosurgery, topical therapies, and systemic medications.
Treatment options for these patients have been limited, but increased understanding of the molecular basis of BCC has enabled potential therapies, such as hedgehog signaling pathway inhibitors, to be developed. Also, when aBCCs are refractory or are recurrent after SI therapy, other treatment modalities such as radiation, traditional chemotherapy or surgical excision need to be considered for optimum patient outcomes.
The dynamics of Basal Cell Carcinoma market is anticipated to change in the coming years owing to the advancement in the diagnostic methodologies, raising awareness of the diseases, incremental healthcare spending across the world, and advancements in research and development undertaking. Key players such as MEDIVIR, Biofrontera Bioscience, Mediwound, AiViva's, Sirnaomics, Pellepharm and various others are involved in developing therapies for Basal Cell Carcinoma.
According to DelveInsight, Basal Cell Carcinoma market in 7MM is expected to witness a major change in the study period 2019-2032.
Analyst Commentary
- The pipeline of Basal Cell Carcinoma is very robust, many potential therapies are being investigated for the treatment of Basal Cell Carcinoma, and it is safe to predict that the treatment space will experience a significant impact on the market during the forecast period.
- The expected introduction of emerging therapies with improved efficacy, more awareness initiatives programs, and further improvement in the diagnosis rate, are likely to boost the growth of the Basal Cell Carcinoma market in the 7MM. Aside from that, the market size of Basal Cell Carcinoma may flourish due to increased research and development, label-expansion of approved therapies into other epilepsy in this field.
- The market growth of Basal Cell Carcinoma may offset by failures and/or discontinuation of the emerging therapies, unaffordable pricing, market access and reimbursement issues, and a scarcity of healthcare specialists.
Basal Cell Carcinoma Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the Basal Cell Carcinoma market or expected to get launched in the market during the study period 2019-2032. The analysis covers Basal Cell Carcinoma market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Note: Detailed emerging therapies assessment will be provided in full report of Basal Cell Carcinoma.
Basal Cell Carcinoma Pipeline Development Activities
The report provides insights into Basal Cell Carcinoma Clinical Trials within Phase II and Phase III stage. It also analyses Basal Cell Carcinoma key players involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Basal Cell Carcinoma emerging therapies.
Learn more about the emerging therapies and key companies active in the therapeutics segment: Basal Cell Carcinoma Pipeline Insight
Reimbursement Scenario in Basal Cell Carcinoma
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
KOL- Views
To keep up with current market trends, we take KOLs and SMEs ' opinions working in the Basal Cell Carcinoma domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Basal Cell Carcinoma market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.
Competitive Intelligence Analysis
We perform Competitive and Market Intelligence analysis of the Basal Cell Carcinoma Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.
| Report Metrics | Details |
| Study Period | 2019 to 2032 |
| Forecast Period | 2023 to 2032 |
| CAGR | |
| Basal Cell Carcinoma Market Size | USD XX by 2032 |
| Basal Cell Carcinoma Key Companies | MedC Biopharma Corporation, AiViva BioPharma, MediWound, Kintara Therapeutics, IO Biotech, Sirnaomics, Aresus Pharma, Epitome Pharmaceuticals, Transgene, Senhwa Biosciences, Palvella Therapeutics, Suzhou Kintor Pharmaceuticals, Leaf Vertical, and Many Others. |
Scope of the Basal Cell Carcinoma Market Report
- The report covers the descriptive overview of Basal Cell Carcinoma, explaining its causes, signs and symptoms, pathophysiology, diagnosis, and currently available therapies
- Comprehensive insight has been provided into the Basal Cell Carcinoma epidemiology and treatment in the 7MM
- Additionally, an all-inclusive account of both the current and emerging therapies for Basal Cell Carcinoma are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
- A detailed review of the Basal Cell Carcinoma market; historical and forecasted is included in the report, covering drug outreach in the 7MM
- Detailed Patient Based Market Forecasting determines the trends shaping and driving the global Basal Cell Carcinoma market
Basal Cell Carcinoma Market Report Highlights
- In the coming years, the Basal Cell Carcinoma market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
- The companies and academics are working to assess challenges and seek opportunities that could influence Basal Cell Carcinoma R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
- Major players are involved in developing therapies for Basal Cell Carcinoma. The launch of emerging therapies will significantly impact the Basal Cell Carcinoma market
- A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Basal Cell Carcinoma
- Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed Basal cell carcinoma clinical trial profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
Basal Cell Carcinoma Report Insights
- Patient Based Market Forecasting
- Basal Cell Carcinoma Therapeutic Approaches
- Basal Cell Carcinoma Pipeline Analysis
- Basal Cell Carcinoma Market Size and Trends
- Basal Cell Carcinoma Market Opportunities
- Impact of upcoming Therapies
Basal Cell Carcinoma Report Key Strengths
- 10 Years Forecast
- 7MM Coverage
- Basal Cell Carcinoma Epidemiology Segmentation
- Key Cross Competition
- Highly Analyzed Market
- Basal Cell Carcinoma Drugs Uptake
Basal Cell Carcinoma Report Assessment
- Basal Cell Carcinoma Current Treatment Practices
- Basal Cell Carcinoma Unmet Needs
- Basal Cell Carcinoma Pipeline Product Profiles
- Basal Cell Carcinoma Market Attractiveness
- Basal Cell Carcinoma Maket Drivers
- Basal Cell Carcinoma Market Barriers
Key Questions Answered In The Basal Cell Carcinoma Market Report
Basal Cell Carcinoma Market Insights:
- What was the Basal Cell Carcinoma drug class share (%) distribution in 2019 and how it would look like in 2032?
- What would be the Basal Cell Carcinoma total market size as well as market size by therapies across the 7MM during the forecast period (2019-2032)?
- What are the key findings of the market across 7MM and which country will have the largest Basal Cell Carcinoma market size during the forecast period (2019-2032)?
- At what CAGR, the Basal Cell Carcinoma market is expected to grow by 7MM during the forecast period (2019-2032)?
- What would be the Basal Cell Carcinoma market outlook across the 7MM during the forecast period (2019-2032)?
- What would be the Basal Cell Carcinoma market growth till 2032, and what will be the resultant market Size in the year 2032?
- How would the unmet needs affect the market dynamics and subsequent analysis of the associated trends?
Basal Cell Carcinoma Epidemiology Insights:
- What are the disease risk, burden, and regional/ethnic differences of Basal Cell Carcinoma?
- What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- What is the historical Basal Cell Carcinoma patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- What would be the forecasted patient pool of Basal Cell Carcinoma in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- Where will be the growth opportunities in the 7MM concerning the patient population about Basal Cell Carcinoma?
- Out of all 7MM countries, which country would have the highest prevalent population of Basal Cell Carcinoma during the forecast period (2019-2032)?
- At what CAGR the patient population is expected to grow by 7MM during the forecast period (2019-2032)?
Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:
- What are the current options for the Basal Cell Carcinoma treatment in addition to the approved therapies?
- What are the current treatment guidelines for the treatment of Basal Cell Carcinoma in the USA, Europe, and Japan?
- What are the Basal Cell Carcinoma marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
- How many companies are developing therapies for the treatment of Basal Cell Carcinoma?
- How many therapies are in-development by each company for Basal Cell Carcinoma treatment?
- How many are emerging therapies in mid-stage, and late stage of development for Basal Cell Carcinoma treatment?
- What are the key collaborations (Industry - Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Basal Cell Carcinoma therapies?
- What are the recent novel therapies, targets, mechanisms of action, and technologies being developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Basal Cell Carcinoma and its status?
- What are the current challenges faced in drug development?
- What are the key designations that have been granted for the emerging therapies for Basal Cell Carcinoma?
- What are the global historical and forecasted markets of Basal Cell Carcinoma?
Reasons to buy Basal Cell Carcinoma Market Report
- The Patient Based Market Forecasting analysis will help in developing business strategies by understanding trends shaping and driving the Basal Cell Carcinoma market
- Organize sales and marketing efforts by identifying the best opportunities for Basal Cell Carcinoma in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
- Organize sales and marketing efforts by identifying the best opportunities for the Basal Cell Carcinoma market
- To understand the future market competition in the Basal Cell Carcinoma market
